Literature DB >> 422302

Pharmacokinetics of l-carnitine in man following intravenous infusion of dl-carnitine.

P G Welling, J H Thomsen, A L Shug, F L Tse.   

Abstract

The pharmacokinetics of l-carnitine were studied in adult male patients following intravenous infusion of dl-carnitine hydrochloride-L-Carnitine appears to distribute into a rapidly perfused and then a more slowly perfused body space following administration. The overall apparent distribution volume Vd (ss) is consistent with extracellular body water. Serum levels of l-carnitine, from two different dose levels were adequately described by a two-compartment model. 80% of the administered dose was recovered in 24 hour post dose urine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422302

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  7 in total

Review 1.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

2.  Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects.

Authors:  P Harper; C E Elwin; G Cederblad
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  L-carnitine transport in kidney of normotensive, Wistar-Kyoto rats: effect of chronic L-carnitine administration.

Authors:  Lucía Gómez-Amores; Alfonso Mate; Carmen M Vázquez
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

4.  Anti-arrhythmic effects of (-)-carnitine chloride and its acetyl analogue on canine late ventricular arrhythmia induced by ligation of the coronary artery as related to improvement of mitochondrial function.

Authors:  S Imai; K Matsui; M Nakazawa; N Takatsuka; K Takeda; H Tamatsu
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

5.  Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects.

Authors:  P Harper; C E Elwin; G Cederblad
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects.

Authors:  T Uematsu; T Itaya; M Nishimoto; Y Takiguchi; A Mizuno; M Nakashima; K Yoshinobu; T Hasebe
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.